You are here

Combination Treatment with Transcranial Magnetic Stimulation and Ketamine for Treatment-resistant Depression


Warning message

This webinar is restricted to registered participants or on-demand registrants. Click the following link to register: Register Here

Combination Treatment with Transcranial Magnetic Stimulation and Ketamine for Treatment-resistant Depression

You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Combination Treatment with Transcranial Magnetic Stimulation and Ketamine for Treatment-resistant Depression

Presentation Overview: 

  1. To understand the literature on the mechanisms of action supporting combination treatment with TMS and ketamine
  2. To identify clinical situation in which combination treatment with TMS and ketamine may be warranted.
  3. To recognize where combination treatment with TMS and ketamine may fit in a treatment algorithm for medication refractory depression.

Date of Release: February 5, 2021

Date of Expiration: February 4, 2023


Cost: Members: $25 | Non-members $50 | Student Members FREE

SPEAKER: C. Sophia Albott, MD

Dr. C. Sophia Albott is the Deputy Vice Chair for Research and an Assistant Professor in the Department of Psychiatry & Behavioral Sciences at the University of Minnesota. Her research focuses on novel interventions (ketamine, transcranial magnetic stimulation, cognitive training) for treating mood (depression) and trauma-related disorders (PTSD). She published the first study of repeated ketamine infusions in veterans with PTSD and currently leads the first randomized controlled trial of repeated ketamine infusions for comorbid PTSD and depression. Dr. Albott’s research uses neuroimaging techniques (MRI) to evaluate structural and functional brain abnormalities in trauma-related disorders (PTSD, depression, secondary traumatic stress). She also established and leads the Ketamine Registry of Minnesota (KaRMa) which is a joint venture between the University of Minnesota and Mayo Clinic tracking long-term outcomes of patients receiving ketamine for depression. She maintains a part-time clinic at the MHealth Outpatient Neuromodulation Clinic where she also participates in clinical research translating her work on the pathophysiological mechanisms underlying disordered responses to trauma. She has received awards from the NIH and the University of Minnesota Medical School, and is currently funded through a K23 Career Development Award from the National Institute of Mental Health.

**As a reminder, you must be logged into the Clinical TMS dashboard to view the recording. If you are having trouble accessing the webinar, please refer to the appropriate access instructions below. 

Member Webinar Access Instructions

Non-Member Webinar Access Instructions


Vertical Tabs

Vertical Tabs

Acknowledgement of Financial and/or In-Kind Commercial Support

No financial or in-kind commercial support was received for this educational activity.

Satisfactory Completion 

Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.   


In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Clinical TMS Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Questions? Email